Cadent Therapeutics to Present at the Jefferies Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 28, 2019--
Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Jefferies Healthcare Conference on Tuesday, June 4, 2019 at 10:00 am ET in New York City.
About Cadent Therapeutics
Cadent Therapeutics is creating breakthrough therapies for the treatment of movement disorders and cognitive impairment. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor and schizophrenia. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 1 clinical studies for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Institutes for Biomedical Research and Slater Technology Fund. For more information, please visit cadenttx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005073/en/
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Cadent Therapeutics
Copyright Business Wire 2019.
PUB: 05/28/2019 07:00 AM/DISC: 05/28/2019 07:01 AM